Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Recalls, complaints & regulation
Tonix Pharmaceuticals Holding (TNXP): clinical trials
Tonix Pharmaceuticals Holding (TNXP) beyond its filings: 2 active clinical trials.
Tonix Pharmaceuticals Holding's latest quarter
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Tonix Pharmaceuticals Holding have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.